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PREDICTING DISENGAGEMENT FROM CARE IN AN EARLY PSYCHOSIS
PATIENT COHORT IN THE UNITED STATES.
Matthew Kruse, Vivek Phutane, and Vinod Srihari. Department of Psychiatry, Yale
University, School of Medicine, New Haven, CT.
The current study aims to assess baseline variables which may predict disengagement
from care among patients with psychosis seeking treatment at an early intervention clinic
in the United States. Based on literature published at sites outside the United States, we
predict that duration of untreated psychosis, global assessment of functioning, forensic
history, family contact, and substance abuse are predictive of disengagement during the
first year of outpatient treatment. Patients were grouped according to whether or not they
disengaged from care in a one year follow-up, and compared them on the above discrete
and continuous variables with chi-square analysis and Student‟s t-tests, respectively.
Although none of the statistical tests reached significance, data trends suggest that longer
duration of untreated psychosis, lower global assessment of functioning, forensic history,
substance abuse, and less family contact may be associated with disengagement from
care.
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Introduction
Psychotic Illness and Treatment Challenges
Schizophrenia and other psychotic disorders are a series of related, typically chronic
conditions that respond best to stable, long-term treatment (1). The lifetime prevalence of
any psychotic disorder is estimated to be approximately three to four percent (2), are
costly to treat, and even with widespread use of antipsychotic pharmacotherapy, continue
to be a major source of lifetime disability (3, 4). The exact reasons some individuals
develop psychosis are still incompletely understood. Etiologically, prominent theories of
schizophrenia and related psychotic illnesses include abnormal neurodevelopmental
models (supported by evidence that patients may have structural brain abnormalities such
as ventricular enlargement prior to onset of illness), neurodegenerative models (supported
by evidence that stable schizophrenic patients who relapse following removal of
antipsychotic medication often are unable to return to prior levels of wellness), and
neurochemical models, with particular suspicion of dopaminergic and glutamatergic
imbalance (5). Indeed, there are many forms of psychotic disorders with varied
constellations of positive (such as hallucinations or disorganized thought) and negative
symptoms (such as flattened affect or catatonia), likely representing a spectrum of
neurobiologically distinct disorders (6). Accordingly, studies have identified a variety of
risk factors associated with psychotic illness, including substance abuse (7), family
history (8, 9), prenatal insults (10), and even geographic setting or culture (11, 12).
Nevertheless, many authors agree that most forms of psychosis are the result of a
complex interaction of genetics and environment (7, 11, 13).
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Apart from the cognitive and functional disabilities inherent to psychosis, literature has
suggested that patients with a psychotic illness are at higher risk for somatic
complications such as obesity, diabetes, and cardiovascular disease (14). These chronic
medical conditions may help explain data showing that the life expectancy of individuals
with schizophrenia or other psychotic disorders may be reduced by 15 to 25 years (1416). There is evidence that the morbidity and mortality associated with psychotic
illnesses may be intrinsically related to the biological processes underlying psychosis. A
review on predisposition for metabolic syndrome and cardiovascular risk in
schizophrenia suggests that present data is conflicting, but drug-naïve patients with
schizophrenia may have greater baseline levels of insulin sensitivity and higher blood
glucose levels than controls (17). In addition, rates of suicide and attempted suicide are
particularly high among patients with psychosis, with a lifetime risk of five percent (18).
Nevertheless, the impact of environmental influences cannot be ignored. First, some
types of unhealthy lifestyle choices tend to occur at higher rates in these patients. A
review of the literature notes that rates of smoking in patients with schizophrenia may be
as high as 85% (much higher than the estimated 23% in the general population of the
United States), and up to 40% of patients with schizophrenia may be smoking more than
30 cigarettes daily. Secondly, the morbidity and mortality associated with psychosis may
be exacerbated by the metabolic and other systemic side effects that commonly occur
with some antipsychotic medications (14, 19). Aside from the risks of medical
disabilities, logistical and financial obstacles may be significant barriers to psychiatric
care for patients with psychosis. A survey of patients with serious mental illness in the
United States revealed that among those who did not seek desired psychiatric care, 46%
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cited lack of insurance coverage or prohibitive out of pocket expenses, and 52% had
situational problems, including uncertainty of where to seek help or time constraints (20).
Among a cohort of first-episode of psychosis (FEP) patients in New Haven, Connecticut,
33% of patients were uninsured at baseline, and among those who were insured, only
29% maintained coverage over the first year of psychiatric treatment. Even among those
who were eligible for public insurance, 38% lost coverage over this period (21). Taken
together, despite the development of multiple generations of antipsychotic medications,
there remains significant room for improvement in the clinical and psychosocial
interventions for patients with psychotic disorders.
Engagement and Disengagement
The previous section outlined the treatment challenges that accompany psychotic
disorders, and began to address the various barriers to care facing many patients suffering
from them. Unfortunately, merely connecting patients with care is inadequate, and
authors agree that maintaining treatment and preventing service disengagement is critical
for producing good clinical outcomes while preventing morbidity, mortality, and
psychosocial decline (18, 22). Before service disengagement can be discussed further, the
definition of term „disengagement‟ should be examined.
Strikingly, despite a rather voluminous body of literature on the topic of disengagement
from psychiatric services, there is no consensus on what constitutes “disengagement.”
For instance, Fischer et al. define disengagement among a cohort of patients with
schizophrenia or bipolar disorder as “a period during which a cohort member had no
documented contact” with his or her mental or medical healthcare providers (23). This
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study identified all disengagement periods greater than three months, but focused most of
their analysis on disengagement periods of 12 months or greater. Kessler et al. defined
disengagement among patients with serious mental illness as having sought psychiatric
care at any time in the preceding 12 months, but not currently seeking treatment for any
reason other than an improvement in symptoms (20). Olfson, meanwhile, simply defines
disengagement as the discontinuation of treatment earlier than intended by a clinician
(24). In an assessment of psychiatric service use of first-time patients in South Verona,
Italy, Tansella provides a more formal definition of disengagement. Service use was
described in terms of „episodes of care‟ and „break values‟ (25). A „break value‟ is
considered the amount of time that must pass between clinical contact before a patient
can be considered disengaged from active treatment. An „episode of care‟, meanwhile, is
the time that passes before a patient hits a given „break value.‟ They calculate patterns of
service use using break periods ranging from seven days to 183 days. As would be
expected, when a seven day break value was used, the median episode of care in their
sample was one day. They reason that only the most acutely ill patients are seen in
outpatient clinic more than once every seven days. Therefore, a seven day break value is
too sensitive, producing excessive disengagement false-positives. After recalculating
using various break values, they found that 90 days appeared to be the optimally sensitive
and specific break value. The authors note that a 90 day break value is consistent with the
clinical needs of patients, and had used this value in prior publications (25).
Nevertheless, literature reviews have suggested that in general, psychiatric patients in the
United States have a disengagement rate of about 20% (24). Among patients with
psychosis, a systematic review uncovered estimates of disengagement rates ranging from
7

24 to 90%. The average rate of disengagement among the 86 studies analyzed, weighted
for sample size, produced an estimate of 26% disengagement rate. The definition of
disengagement in this review cannot be defined, as rates of disengagement were assessed
according to the definition used in each study included in the meta-analysis. (26)
Predicting Disengagement
Even if there is ongoing disagreement in the literature on what constitutes
disengagement, and what the true rate of disengagement is among various patient
populations, there have been factors associated with greater risk for disengagement from
care both in cases of psychotic illness as well as in general psychiatric populations.
Namely, younger age (24, 27), living apart from family (28, 29), lack of insurance (30),
forensic history (29, 31), less use of available services (27), longer duration of untreated
psychosis (DUP) (32), lower baseline global assessment of functioning (GAF) (28), lack
of insight (33), and persistent substance abuse (24, 28, 29) often correlate with higher
rates of service disengagement.
In addition to these factors, early stage of treatment is a particularly critical time for
preventing disengagement from care. Data has shown that first-time psychiatric patients
are almost six times more likely to drop out of treatment if they have had fewer than three
clinical visits, with authors hypothesizing that once rapport and trust is established over
time, risk of disengagement decreases (24). Among patients with psychotic illnesses, side
effects of antipsychotic medication, which may occur early in treatment, could be
contributing the high rates of disengagement early in treatment. One study demonstrated
that a 12 week course of some antipsychotics in treatment naive adolescents produced
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significant weight gain and triglyceride elevation that was not observed in unmedicated
controls (34). These side effects may provide incentives for patients to disengage from
care and discontinue medication during the first few weeks of treatment if a strong
therapeutic relationship has yet to be established. The Clinical Antipsychotic Trials of
Intervention Effectiveness (CATIE) study indeed demonstrated that among an array of
first- and second-generation antipsychotics, 74% of patients discontinued their
antipsychotic medication within 18 months, often due to side effects or perceived lack of
efficacy (19).
Duration of Untreated Psychosis
Of the factors listed above, much emphasis has been placed in the literature on DUP,
defined as the lapse in time between the onset of psychosis and the start of treatment.
DUP receives emphasis not only as a predictor of disengagement, and poor clinical
outcomes, but also as a valuable tool for examining the natural progression of psychotic
illness (35-37). An examination of DUP in patients living in Nova Scotia, Canada
showed that longer DUP is associated with more severe negative symptoms and social
withdrawal at baseline, in addition to more severe positive symptoms and lower GAF
scores six months into treatment (35). Similarly, Schimmelmann et al. demonstrated that
longer DUP is associated with worse illness severity, positive symptom remission rate,
and general functioning after 18 months of treatment (37). A meta-analysis of 26 studies
demonstrated that DUP correlated significantly with worse depression, anxiety, positive
and negative symptoms, social functioning, and overall quality of life 12 months into
treatment (32).
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Conversely, a study of first-episode schizophrenia patients in West London found only
older age to be significantly associated with DUP longer than 26 weeks. They found
some data trends linking longer DUP and more errors on a computerized neurocognitive
task, as well as longer duration of untreated illness (but not DUP) with poorer initial
response to antipsychotics. (Duration of untreated illness was defined as DUP plus the
length of any prodromal symptoms.) Though the sample size was limited (n = 53), the
authors were nevertheless skeptical that untreated psychosis may be conferring any
inherent challenges to treatment once a connection to care is established. Instead, they
hypothesize that longer DUP may be linked to confounding variables such as social
isolation or less socially-conspicuous negative symptomology which may prolong the
time to seeking treatment (38). Polari et al. stress that poor adherence to medication while
attending medical appointments might be considered part of the DUP period, potentially
accounting for some of the variation in findings on the effect of DUP in studies that
might not necessarily be measuring this metric (36).
First-Episode Psychosis and Early Intervention
The potential importance and benefits of limiting DUP, combined with the insight that
several predictors of disengagement, including younger age and early treatment phase,
tend to co-segregate in patients with first-episode psychosis (FEP), has rendered this
population of particular importance to investigators interested in optimizing outcomes in
patients with psychotic illness. A survey in the U.K. of patients with FEP found that the
67% were between 16 and 30 years old, 86% were unemployed, and 72% had
discontinued education by the age 16 (39). Sixty-two percent of a FEP cohort in Australia
was found to have a substance use disorder at baseline assessment (40). These
10

demographic and socioeconomic trends in FEP underscore concerns that intervention
should be initiated as early as possible to prevent the medical, psychiatric, and
psychosocial decline that is common in this population by the time care is initiated (14,
41).
Aside from establishing care, the particularly high risk of disengagement within the first
two appointments of care following discharge from an emergency department or inpatient
psychiatric unit has prompted investigators to stress that it is critical to establish a strong
clinical relationship as early as possible (24). This insight, combined with the challenges
in treating FEP discussed, has inspired a growing number of specialized early
intervention clinics aimed at initiating treatment as early as possible in the course of any
psychotic illness, either in the prodromal phase (prior to the onset of frank psychosis) or
as soon as possible after the onset of psychosis, effectively reducing DUP (42).
One of the flagship programs studying the effects of specialized early intervention in FEP
was the Buckingham study, established in 1984. The program was established in rural
England to improve the recognition and prompt treatment of patients in the earliest stages
of serious mental illness, employing several key strategies. Initial psychiatric evaluations
were performed at a location convenient to the patient. Primary care providers were given
additional training and screening tools to improve their detection of serious mental illness
during routine checkups. Specialized psychiatric consultations were made readily
available, often performed collaboratively with a patient‟s primary care provider (43).
Once patients were identified as potentially in the early stages of schizophrenia,
specialized treatment interventions were immediately implemented. First, patients were

11

educated on all parameters of their illness, with an emphasis on the good prognosis that
may be achieved with stable, long-term treatments. Second, sources of a patient‟s
stressors were identified, especially in cases where precipitating life events were
suspected to have triggered psychiatric symptoms, and stress management was instituted
with an intensity appropriate to a particular patient‟s needs. Finally, these psychosocial
interventions were complemented by low-dose antipsychotic medication, targeted at the
correction of a particular deficit, such as insomnia or thought disturbances, and
discontinued when the target symptom had resolved. Once prodromal symptoms had
resolved, primary care providers took responsibility for close, long-term monitoring for
any signs of relapse (43).
Many of the key features of the Buckingham study have been implemented in later early
intervention programs, including lower-dose antipsychotics, comprehensive case
management, supportive psychotherapy, psychoeducation for patients and families, and
group cognitive-behavioral therapy (41, 44-46).
The rationale behind the continued and growing support for specialized early intervention
clinics for FEP is multifaceted. First, early specialized intervention may help prevent
functional decline and improve clinical outcomes, applying a preventive philosophy to
psychosis treatment. By asserting more intensive outpatient follow-up early in the course
of illness, the degenerative neurobiological changes that have been hypothesized to
accompany untreated psychosis may be avoided (5). In addition, patients with FEP often
report adverse events in the time leading up to their first connection with psychiatric care.
One survey revealed that significant functional disability develops over the course of
untreated psychosis, and 14% of FEP patients in Melbourne attempted suicide prior to
12

treatment (41). A review by Goff et al. also points out that rates of infectious disease,
including influenza, HIV, and hepatitis C is particularly high among individuals with
serious mental illness, due in large part to unhealthy lifestyle habits that occur with
higher frequency in this patient population. Findings such as these provide a compelling
argument for earlier, more assertive intervention driven by the ideals of preventive care
(14). A comparison of early specialized versus standard treatment for FEP patients in
Denmark suggests that the specialized approach produced superior positive and negative
symptom relief at one and two years into treatment. In addition, the group receiving
specialized treatment demonstrated lower rates of substance abuse, and greater service
engagement (46). A similar study of 144 first- and second-episode psychosis patients by
the Lambeth Early Onset team in the U.K. failed to find a significant advantage for
specialized treatment in symptom reduction at 18 months, but did report that specialized
treatment produced superior measures of quality of life and global functioning at 18
months (47). Psychiatric patients with access to dual modality treatment, including both
pharmacotherapy and talk therapy, have been shown to be less likely to dropout from
care (30). In addition, Iyer et al. demonstrated that aside from symptom relief, patients
with FEP in Chennai, India most frequently cited vocational, educational, and
interpersonal improvement as their highest priority goals for treatment. By emphasizing
these global issues in treatment through modalities including vocational rehabilitation and
family education, early intervention clinics may be aligning themselves more closely with
a patient‟s personal goals, helping build strong therapeutic alliances more efficiently (45).
This may help explain an analysis of an early intervention clinic in the U.K. which
revealed lower dropout rates than standard treatment controls (44).
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Economically, early intervention may yield additional benefit, especially in terms of costeffectiveness of treatment, more optimal allocation of scarce resources, and improved
educational and vocational outcomes. As mentioned previously, early intervention clinics
aim to provide more intensive outpatient care with an emphasis on crisis prevention. An
analysis of patients with psychosis in the U.K. demonstrated that while 86% of FEP
patients were unemployed at initiation of treatment, unemployment reached 100% in
patients with a second episode of psychosis (39). If patients are identified and treated
earlier, the psychosocial decline associated with more severe cases of psychosis may
theoretically be prevented, reducing rates of unemployment.
A cost-effectiveness analysis was performed at an early intervention for psychosis clinic
in Milan, Italy. In both groups, treatment was administered for approximately five years,
and both groups demonstrated significant clinical improvement, as measured by the
Health of Nation Outcome Scales (HoNOS), an inventory measuring a variety of clinical
and social outcomes relevant to psychotic illness. The average daily costs of treatment in
the early intervention group and the standard care group were similar (€22.60 and €23.00
per patient, respectively), but the specialized treatment group demonstrated a larger
absolute decrease in the HoNOS measure of illness severity. The authors concluded that
specialized treatment is cheaper per unit of improvement in symptoms and global
functioning (€4802 versus €9871 per unit reduction in severity on the HoNOS) . They
additionally noted that more expensive outpatient interventions such as psychotherapy
rendered specialized treatment more expensive in the first two years of treatment, but
became less expensive than standard treatment in the last three years, likely due to a trend
in fewer admissions to and shorter stays in inpatient care facilities (though this data trend
14

fell short of statistical significance). Standard care, meanwhile, became linearly more
expensive, on average, over the five year course of treatment, again, potentially due to
greater use of inpatient psychiatric services among this patient group (48). Indeed,
analyses of early intervention clinics in Melbourne, Australia (49) and the U.K. (44)
demonstrated statistically significant reductions in hospitalization rate compared to
standard treatment controls.
It may be too soon to draw definitive conclusions on the benefits of early intervention
clinics. A recent Cochrane Review article found that specialized early intervention for
FEP did improve compliance with treatment, but failed to find statistically significant
benefits on other outcome metrics, including hospitalization, relapse, and suicide. The
authors, however, noted the limited number of studies from which to draw conclusions,
and underscored the importance for more, higher-powered studies to more fully elucidate
potential benefits of early intervention, and whether these benefits are maintained over
time (50).
Criticism of Early Intervention
Despite the urging for more data and the efforts on the parts of investigators, the
movement towards earlier intervention for psychosis is not without its critics. Pelosi et al.
argue that intervention earlier in the course of illness – particularly during the prodromal
phase of psychosis – will lead to a greater number of patients being inappropriately
treated for a psychosis who would never have developed the illness, noting that
symptoms of a prodromal psychotic illness are far more common than psychotic illnesses
themselves. Aside from the risks of treating patients prior to full onset of psychosis, he
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additionally notes that some patients with psychosis will improve spontaneously without
treatment, with earlier interventions at greater risk of providing unnecessary treatment to
these patients (51, 52).
Pelosi additionally notes that the growing number of early intervention clinics may be
diverting the limited resources of the already strained mental healthcare infrastructure
away from the majority of patients with a long history of psychotic illness to better fit the
needs of a select few early in the course of illness. Furthermore, he suggests that by
discharging patients to standard care following a finite course of treatment during more
critical periods of intervention (often the first few years following onset of psychosis),
early intervention clinics are providing the very same fragmented care that they were
designed to avoid (51, 52). Finally, some in the psychiatric community question whether
the selection criteria of many early intervention clinics, such as limited duration of
psychotic illness and little-to-no prior courses of antipsychotic medication, may be
introducing a selection bias for patients with better prognoses or who may have
spontaneously improved without intervention. Aside from providing inappropriate
treatment, such recruitment practices may in fact be skewing data towards better
outcomes, obscuring the true benefit of specialized early intervention (53). The concerns
regarding early intervention are certainly valid. Even as the behavioral and neurologic
antecedents to schizophrenia and other psychotic illnesses become more refined, there
remains a considerable challenge in predicting future cases of psychotic illnesses with
much specificity. Some authors note, however, that this lack of specificity may actually
potentiate the benefit of early intervention through prevention of behaviorally or
biologically related conditions such as bipolar disorder, as long as the dangers of
16

treatment are minimized (54). As long as antipsychotic medication remains a treatment
mainstay, however, side effects of intervention will continue to be a legitimate concern.
In a review of the literature on metabolic side effects of antipsychotic medication in FEP
patients, Foley and Morley found that significant increases in weight, insulin resistance,
cholesterol, and fasting glucose could be present within six to eight weeks (55). On the
other hand, the multiple modality treatments for psychosis characteristic of early
intervention, with a use of lower-dose antipsychotic medication, may reduce the risks of
extra-pyramidal symptoms or metabolic side effects of treatment (56). In a review on the
use of antipsychotic medication in FEP, Francey et al. even suggest that psychosocial
interventions alone may be sufficient in the treatment of some cases of early psychosis, evading
their cardiovascular risks completely (57). Furthermore, Conus et al. note that FEP patients

have typically experienced significant social and psychiatric decline prior to engagement
with an early intervention clinic. As a result, they suggest treatment during the prodrome
of psychosis may be necessary to truly optimize outcomes, and treating only after the
onset of a full psychosis, as critics of early intervention recommend, may be too late (41).
Concerns regarding the fragmented care of patients discharged from specialized treatment
to standard care following the critical period of illness has been examined by several
studies. A two year early intervention (OPUS trial) in Denmark found that the clinical
benefits of specialized treatment at two years were no longer present in at a five year
follow-up (58). A clinic in Canada, however, provides specialized FEP care for five
years, though with much lower intensity after the second year of treatment, and found
persistent improvement in symptoms at a five year follow-up, lending support for the
need of longer continuity of care in early intervention clinics (59). In a separate followup assessment of Canadian FEP patients discharged to standard care following three
17

years of specialized intervention, Addington and Addington find that patients maintained
benefits on metrics of positive symptoms, and continued improvement in negative
symptomology and quality of life scales over a four- to five-year follow-up period.
(Although, only approximately half of patients could be followed up following discharge,
potentially biasing results towards patients who retained higher functioning.) (60)
Even though the rationale and promise of early intervention clinics has its critics, a
growing number of elements of specialized early intervention are becoming validated by
experts. The Schizophrenia Patient Outcomes Research Team (PORT) treatment
recommendations is a review published periodically which analyzes the current literature
to assess which psychosocial interventions for schizophrenia are supported by evidence,
and makes recommendations for standard treatments. In the 2009 update of PORT, they
recommend the use of Assertive Community Treatment involving a multidisciplinary
treatment team and higher frequency of contact between patients and clinicians. Also
recommended is a broader treatment focus, emphasizing vocational and interpersonal
skills, access to cognitive behavioral therapy, and family education. At the time of
writing the 2009 PORT recommendations, there was insufficient evidence for the authors
to officially endorse psychosocial treatments for recent onset schizophrenia. They
nevertheless express optimism for this intervention, noting the early intervention data is
“witnessing substantial progress,” and note that their inability to officially endorse early
intervention was “primarily due to small numbers of studies for any given intervention
and some inconsistencies among the findings” (1).
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Early Intervention in the United States
Helping to answer the call for more data regarding early intervention for psychosis, the
Specialized Treatment Early in Psychosis (STEP) program at the Connecticut Mental
Health Center in New Haven, CT, is an NIH-funded pilot program that aims to
investigate the effects of multidisciplinary, evidence-based intensive outpatient
intervention in the United States. Briefly, its focus is to replicate and further elucidate the
benefit of early intervention in psychosis in a cohort of FEP patients in the United States
using a pragmatic randomized controlled trial paradigm (described in detail in the
following methods section).
STEP is one of the first specialized early intervention in psychosis clinics in the United
States (61). As noted previously, the benefit of the psychiatric interventions assessed by
early intervention clinics may vary between geographic regions due to variances in
standard care protocols, making extrapolation of currently available data to the United
States unreliable and necessitating replication studies (62).
Statement of Purpose
The current study aims to explore data on disengagement from an early intervention
psychosis clinic in the northeast United States. Our first aim is to begin elucidating the
effects of early intervention in the United States, where there is currently little published
data, focusing on predictors of disengagement in an FEP cohort. The fragmented care that
is typically available to patients in the US, particularly in psychiatric populations, renders
engagement in a strong, long-lasting connection to a mental healthcare facility of
particular importance (62, 63). We will explore whether previously identified predictors
19

of disengagement can be replicated in our patient sample. Specifically, we hypothesize
that younger age, longer DUP, lower baseline GAF, forensic history, less family contact,
and substance abuse will associate with higher rates of service disengagement. In
addition, as many studies on disengagement from service seem to rely on varied or even
vague definitions of disengagement (64), we hope to contribute data centered on a
clinically reasoned, objectively measurable definition of disengagement.
Method
Setting
The current study was conducted at Connecticut Mental Health Center (CMHC), a
publicly-owned mental health treatment facility that operates as part of the Connecticut
Department of Mental Health and Addiction Services (DMHAS). CMHC and much of its
clinical staff are additionally affiliated with the Yale University School of Medicine.
CMHC provides inpatient and outpatient mental health care to uninsured or publicly
insured-patients over the age of 18 living in New Haven, CT and surrounding
communities, representing a catchment of approximately 200,000 eligible individuals
(61).
Clinical data was obtained from the Specialized Treatment Early in Psychosis (STEP) at
CMHC, an NIH-funded pilot program designed to investigate the clinical and economic
benefit of evidence-based interventions early in the course of psychosis. STEP was
designed as a pragmatic randomized controlled trial that enrolled all patients early in the
course of a psychotic illness (61). To be eligible for enrollment in STEP, patients have be
over 18 years of age, currently suffering from first episode of psychosis (FEP), and have
20

fewer than eight weeks of lifetime treatment with an antipsychotic medication. Patients
need not be eligible for public-sector care, and those with co-morbid psychiatric illnesses
are eligible as long as there is no developmental or intellectual disability present. Once
enrolled in STEP, patients are assigned to either STEP treatment at CMHC or
randomized out to a control “treatment as usual” (TAU) group, receiving care at either
CMHC or with a private mental health practitioner. Patients enrolled to receive care from
STEP do so free of charge. The length of treatment is determined individually by each
patient‟s symptom profile, response to treatment, and clinical needs.
The majority of patients enrolled in the STEP study are recruited either by referral from
Yale Psychiatric Hospital following admission or from regional hospitals.
STEP employs several treatment strategies for early psychosis patients. Aside from
standard antipsychotic pharmacotherapy, patients also have access to group cognitivebehavioral therapy. Individual case managers assist patients with the educational and
vocational difficulties that are common among patients with psychotic illnesses. In
addition, assertive interventions, including frequent clinical contact with a primary
clinician (typically a social worker or psychiatric nurse) as well as phone and written
appointment reminders to patients, aim to decrease clinical drop-out from care. After
enrollment in the STEP study, outcome data is gathered on each patient at baseline and 6
month intervals (61). Data collected is described in more detail in a later section.
Patients
The current study examines patients enrolled in the experimental arm of STEP treatment.
In accordance with STEP‟s research protocol, all patients were between ages 18 and 45 at
21

time of enrollment in STEP, suffering from a first episode of a psychotic illness.
Appropriate diagnosis for inclusion in STEP was determined by guidelines published in
the DSM-IV-TR (6), as assessed by clinical evaluation and the Structured Clinical
Interview for DSM-IV (SCID) and chart review by a psychiatrist or psychologist on staff
at STEP. Exclusion criteria include evidence for substance-induced psychosis, prior
episodes of diagnosed psychosis, or prior antipsychotic pharmacotherapy of greater than
eight weeks (61). All patients were retrospectively evaluated over a period of one year
following enrollment in STEP. Patients enrolled for less than one year at the time of
analysis, or for whom complete clinical records were not available, were excluded.
Assessment of Service Disengagement
Patients were classified as having either remained engaged or disengaged over the first
year of STEP treatment. Disengagement was defined as having been out of contact with
all STEP service providers for a period of 3 months or greater during their first year of
outpatient follow-up, even if they did eventually return to care. Clinical contact was
assessed by chart review. Attendance to appointments was confirmed by clinic notes, and
non-attendance was confirmed by lapses in progress notes and records indicating missed
appointments. Engagement was tracked with a one month resolution. In cases of service
disengagement, the month of the last appointment attended was considered the month
when disengagement occurred.
The one year follow-up period and current definition of disengagement were chosen for
several reasons. First, as noted, literature suggests that the earliest stages of clinical care
following a first episode of psychosis may be the most critical period for establishment of
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a strong therapeutic relationship and optimizing clinical and functional outcomes (24), so
the decision was made to focus on the first year of treatment. From a treatment
standpoint, a period of no clinical contact of three months or greater within the first year
of care following FEP would not be consistent with the assertive treatment modality
employed by STEP, and we considered a three month absence a reasonable indicator of a
patient‟s failure to attend scheduled appointments. Our three month definition of
disengagement is additionally supported by the above-mentioned analysis by Tansella, et
al. which suggests a shorter period may be too sensitive, inappropriately labeling active
patients as disengaged, and longer periods may inappropriately label patients who only
sporadically attend appointments, as fully engaged (25). In addition, the primary
importance for investigating predictors of and reducing rates of disengagement is to
improve outcomes by effecting greater continuity of care (64). Therefore, we consider
any instances of disengagement an indicator that a patient is not receiving optimal
continuity of care, and have classified patients as disengaged even if they eventually
return to care during the one year follow-up period. As the current study is not concerned
with patients who involuntarily disengage from services, patients who move away,
become incarcerated, or expire during the one year follow-up period have been excluded.
Measures
Patients enrolled in STEP are evaluated at baseline. Measures include basic
demographics including age and address, current and past medications, medical history,
the Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCIDCV) (65), Positive and Negative Syndrome Scale (PANSS) (66), Columbia Suicide
Severity Rating Scale (C-SSRS) (67), Global Assessment of Functioning Scale (GAF)
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(6), Heinrich‟s Quality of Life (QOL) (68), Alcohol Use and Drug Use Scales
(AUS/DUS) (69), Abnormal Involuntary Movement Scale (AIMS) (70), modified Social
Functioning Scale (71), and a modified Service Use and Resources Form (SURF) (72).
Patients receive follow-up measures every six months, for which they are compensated
50 dollars. All evaluations are adminstered by a trained STEP affiliated clinician. These
measures provided the demographic, educational, GAF, symptom profile, and forensic
data employed in the current study. Service use was gathered from the modified SURF
scale and medical chart review. These measures are repeated every six months if the
patient is still in contact.
Statistical Analysis
Patients were grouped as being “engaged” or “disengaged” according to criteria
described earlier in the methods section. We used Student‟s t-test to measure differences
between these two populations on several continuous metrics, including age, duration of
untreated psychosis (DUP), and baseline Global Assessment of Functioning (GAF).
Differences in discrete variables, including level of family contact, forensic history, and
baseline substance abuse were assessed by chi-square analysis. Family contact was
converted to an indicator variable of 0, 1, or 2. Family status of “0” indicates that the
patient has no contact with his or her family at the time of baseline assessment, “1”
indicates the patient is in contact with his or her family but does not reside with them, and
“2” indicates that the patient is currently residing with his or her family. In cases where a
patient becomes disengaged, service utilization is calculated only for the months leading
up to, but not including, the final month of engagement. We additionally assessed
substance abuse at baseline and at 6 months, as prior literature has found a stronger
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correlation between persistent substance abuse and disengagement than baseline
substance abuse (28), though our analysis focuses on baseline substance abuse, since our
focus is primarily in predicting risk of disengagement upon initiation of care
All statistical analyses were performed using SPSS (IBM Corporation).
Research Approval and Collaboration
The STEP research protocol and all associated data analysis included in the current study
was approved by the Human Investigation Committee at Yale University School of
Medicine, New Haven, CT. All participants provided written informed consent
authorizing use of clinical and demographic data for analyses. The current study was
conceptualized by Matthew Kruse, Dr. Vivek Phutane, and Dr. Vinod Srihari. Mr. Kruse
and Dr. Phutane gathered all clinical data and performed the statistical analysis. Mr.
Kruse composed the initial and final versions of the current thesis, and Drs. Phutane and
Srihari reviewed the first draft.
Results
Tables 1 and 2 display the investigated variables of the patient groups including age and
gender. The mean age of patients in the current study was relatively young in both groups
at approximately 20 years. The “engagement” group ages ranged from 17 to 30. The
“disengagement” group ages ranged from 17 to 28. The patient population was
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predominantly male (32 out of 39, or 82%).

Age (Years)

Engagement Group
Disengagement Group

Mean (S.D.)
20.30 (7.94)
20.58 (2.59)

t

Sig. (2-tailed)

0.149

0.883

DUP (Weeks)

Engagement Group
Disengagement Group

21.50 (23.33)
27.95 (28.17)

0.776

0.443

Baseline GAF

Engagement Group
Disengagement Group

35.70 (6.46)
32.47 (10.40)

-1.157

0.256

Table 1. Continuous variables and t-test results.
All patients in the current study carried a clinical diagnosis of schizophrenia,
schizophreniform disorder, schizoaffective disorder, or psychosis not otherwise specified.
Disengagement Rate
Among the 39 patients examined in the current study, 19 (49%) disengaged over the
course of the first year. Among patients in the disengagement group, the most likely time
for initial disengagement to occur was within the first three months of outpatient care,
representing nine of 19 (36.8%) disengagement cases. Overall, the average time to initial
disengagement was 3 months. Among the 19 patients who disengaged, 5 (26.3%)
reinitiated clinical contact at some point before the end of the year follow-up. Figure 1
demonstrates a relatively steep drop-off of engagement in the initial months of our
follow-up period.
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Figure 1. Patients with no disengagement periods in first year of treatment

Predictive Variables
Neither group demonstrated significant difference on any of the continuous variables
examined, including age (t = 0.15; p = 0.88), clinic visits per month of engagement (t =
1.75; p = 0.09), DUP (t = 0.78; p = 0.443) or baseline GAF (t = -1.16; p = 0.26) (Table
1). Similarly, none of the discrete variables were significantly different between the
engagement and disengagement groups, including gender (2 = 0.24; p = 0.62), contact
with family (2 = 3.7; p = 0.16), forensic history (2 = 1.76; p = 0.18), or baseline
substance abuse (2 = 1.25; p = 0.264) (Table 2). It was not clear whether these variables
followed a normal distribution, but replication with non-parametric statistical tests did not
yield different results.
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Engaged

Disengaged

Chi-Square

Sig. (2-sided)

Male
Female

17 (43.6%)
3 (7.8%)

15 (38.5%)
4 (10.3%)

0.242

0.622

Living Alone, No Contact
Living Alone with Contact
Living with Family

1 (2.6%)
2 (5.1%)
17 (43.6%)

4 (10.3%)
4 (10.3%)
11 (28.2%)

3.729

0.155

Forensic History
No Forensic History

2 (5.1%)
18 (46.2%)

5 (12.8%)
14 (35.9%)

1.761

0.184

Substance Abuse (baseline)
No Substance Abuse (baseline)

8 (20.5%)
12 (30.8%)

11 (28.2%)
8 (20.5%)

1.249

0.264

Table 2. Discrete variables and chi-square results.
Although there were no significant differences in the two groups for any of the variables
examined, some patterns emerged upon review of our data. The mean DUP was slightly
higher in the disengagement group (27.95;  = 28.17) than the engagement group (21.5;
 = 21.5) though standard deviations were large, and statistical significance was not
achieved. The mean baseline GAF was higher in the engagement group (35.7;  = 6.46)
than the disengagement group (32.47;  = 10.4), but again not significantly so. In
addition, the disengagement group seemed to have less contact with family. Of the five
patients in the current sample who live alone with no contact with family, four (80%)
were in the disengagement group. Of the six patients who live alone yet maintain contact
with family, four (66%) were in the disengagement group. Among the remaining 28
patients who live with family, only 11 (39%) of them disengaged from care. Despite a
lack of statistical significance, all of these factors trended in the direction that we would
have predicted from the literature (24, 28, 29, 32).
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Discussion
Specialized treatment for first episode psychosis is a growing trend internationally, with
mixed yet promising data being published from clinics in locations including Australia
(28), Canada (60), and the U.K. (47). Strengths of the current study include being among
the first examinations of disengagement patterns associated with specialized early
psychosis interventions in the United States. Our data and current definition of
disengagement strives to maximize accuracy in identifying truly disengaged patients
based on clinical attendance data, supported by prior disengagement analyses (25).
Furthermore, our presentation of the data and unambiguous definitions of disengagement
aims to facilitate future meta-analyses as more data is published on patient cohorts in the
United States.
Key Findings
None of the variables examined in the current study were significantly different between
the two groups examined in the current study. The lack of significance may have resulted
from insufficient statistical power caused by a relatively small sample size.
Although we did not uncover any variables that were significantly associated with
disengagement in the first year of outpatient follow-up in FEP, the data on DUP, baseline
GAF, connection with family, forensic history, and substance abuse trended in the same
direction as would have been predicted in the literature. This consistency across all
variables with previously published findings discussed in our introduction suggests our
data trends may not be spurious findings, and may be an indicator of a type II statistical
error stemming from an underpowered analysis.
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Age
We failed to find any relationship between age and disengagement patterns in the current
study. The mean ages of the engagement and disengagement groups were very similar
(20.30 and 20.58 years, respectively). The standard deviation in the ages, conversely,
were strikingly dissimilar between the engagement and disengagement groups (7.94 and
2.59 years, respectively). A post-hoc Levene‟s Test for Equality of Variances on the age
variable was performed, revealing the variances to be significantly different (F = 5.28; p
= 0.027). This data may suggest a unimodal disengagement risk over the age range of the
current patient sample. In other words, those patients either at the lower or higher end of
the current age distribution may be more prone to stay engaged in care, while those in the
middle are at a relatively higher risk of dropout. Reasons for this distribution would be
merely speculative at this point. Although literature reviews on schizophrenia have linked
younger age to higher rates of disengagement, it might be reasonable to suggest that the
risk of disengagement by younger patients may be overcome by the protective factor of
living with parents (a high likelihood in the younger patients in the current study who are
under 20 years old) (22). Older patients, meanwhile, may be more likely to remain
engaged for the same reasons proposed by earlier studies, such as a correlation of later
onset FEP with lower severity of illness or greater insight (30, 39). Our findings raise the
possibility of a critical age of onset for psychosis that renders patients at a higher risk for
disengagement, arising from the aggregate clinical and demographic factors that cosegregate with that particular age range. On the other hand, if the predictive power of age
is merely a result of co-segregation of other factors, a direct measurement of those other
factors may be a more powerful measure for risk of service disengagement.
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Forensic History
Only two patients in the engagement group have a forensic history, as compared to five in
the disengagement group, a trend consistent with prior associations of forensic history
with disengagement (31). It is still unclear why forensic history is associated with
disengagement from healthcare services, though Lecomte et al. suggest that individuals
who have a history of exposure to violence, abuse, or other forms of trauma are more
likely to commit crimes themselves later in life. These same individuals, as a result of
traumatic exposures, may develop impaired interpersonal dynamics, including an
inherent mistrust of the status and authority of a healthcare provider. Hence, a history of
trauma may be the confounding variable linking forensic history with service
disengagement (31).
Social Support
A trend in family contact is consistent with the literature on disengagement patterns in
psychiatric patient populations. Four patients in the disengagement group (21%) live
alone with no contact with family. Meanwhile, only one patient in the engagement group
(5%) lives alone with no contact with family. It is plausible that patients living alone with
no contact with family may have difficulty establishing or maintaining relationships.
These difficulties could extend beyond family or social circles, and form a barrier to
establishing strong therapeutic relationships with healthcare providers. Alternatively,
patients that have fewer social contacts may experience logistical impediments to care,
including fewer social contacts to help remember appointments or greater difficulty
arranging for transportation. The latter hypothesis introduces legitimate concerns about
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why some patients may disengage from care. Patients who do not have access to
transportation, or must financially support themselves and cannot take time off work,
may stop showing up to appointments even if a strong therapeutic relationship is
established. As one may suspect, an assessment of barriers to care in the United States
revealed such difficulties to be common. Specifically, among individual with serious
mental illness who recognized a need for psychiatric treatment, 52% reported prohibitive
logistical barriers, such as being unsure where to seek help, or not having the time to
attend appointments (31). Accordingly, the ease with which patients can attend
appointments should be assessed by clinicians early in a course of treatment. The current
study did not examine the reasons patients dropped out of treatment. Future studies with
this and other data sets should explore the reasons care was discontinued, to assess any
barriers to care that may be present and provide strategies to further improve engagement.
Substance Abuse
At baseline assessment, eight patients in the engaged population reported some element
of substance abuse. By six months, this number had increased to 12 (data not shown).
Prior literature has shown that persistent substance abuse (but not baseline substance
abuse) is associated with greater risk of disengagement from treatment (24), and lower
rates of positive symptom remission (40). One explanation for this phenomenon is that
patients who continue to abuse substances throughout their course of treatment may be
less receptive to the advice of their healthcare providers, leading to poorer medication
compliance and eventual discontinuation of clinical care. Alternatively, patients with
persistent substance abuse may be self-medicating due to greater severity of illness or
poor response to treatment. These patients may perceive formal medical care as being
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less beneficial, which has been shown to increase the likelihood of disengagement (64).
In the current study, the rate of substance abuse increased in the patients that remained
engaged in treatment. It is unclear why this pattern was observed. On one hand, all of the
patients in the current study are undergoing a first-episode of illness. It is possible that
while adjusting to their illness, some patients might be predisposed to substance abuse as
a form of self-medication, as speculated above. Indeed, a similar increase in substance
abuse was noted in the disengagement group (11 patients at baseline, up to 14 at six
months) (data not shown). The similar pattern between the engagement and
disengagement groups might suggest that risks of substance abuse may be related to the
inherent nature and symptoms of psychotic disorders rather than the external factors
examined in the current study. Alternatively, as with the other comparisons in the current
study, there is a chance that a limited sample size may lead to underpowered analysis,
obscuring patterns that may otherwise be present.
DUP
There was a trend for higher DUP in the disengagement group in the current dataset.
Although this difference was not significant, the data was in the direction we would have
predicted from prior literature (32). As with many variables associated with
disengagement from care, authors have speculated on why this relationship may exist, but
the precise dynamics are still unclear. As noted before, some investigators speculate that
schizophrenia and related disorders may reflect a neurodegenerative process which would
be exacerbated by prolonged DUP and produce greater treatment and engagement
challenges at baseline (5). Others hold that DUP may be confounded by associations with
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other variables that independently predict delays in seeking treatment and poor
engagement in services, such as poor social supports (38).
Baseline GAF
GAF is a subjective numeric scale used by mental health professionals to assess how well
patients manage daily obligations and stressors, including social functioning,
psychological coping, and vocational or educational performance (6). It is perhaps not
surprising that prior studies have linked lower GAF scores to higher rates of
disengagement, as difficulty or unwillingness in maintaining a relationship with mental
health clinicians is precisely the type of poor functioning GAF is meant to measure.
Similarly, by virtue of the metrics that it measures, GAF may correlate with illness
severity. The alignment of GAF with both disengagement and illness severity may
explain at least a portion of the correlation of disengagement with worse clinical
outcomes. In agreement with previous studies on disengagement (28), our data trends
suggest that lower GAF may be associated with higher disengagement rates in our patient
population. As with other variables currently studied, a repeated study with a larger
sample may yield a statistically significant relationship.
Limitations
Many of the studies on specialized psychiatric cohorts, including FEP patients receiving
specialized early intervention, are limited by sample size. The current study is similarly
limited by a sample of only 39 patients. In addition, much of the literature on service
disengagement is plagued by the current disagreement on what constitutes
disengagement, as illustrated earlier. Because our data was collected retrospectively,
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some measures that would have made some of our analyses more meaningful could not
be collected. Although methods for determining disengagement vary, most definitions
discussed so far are based on the presence (or not) of clinical contact. Meanwhile, some
argue that measuring disengagement should be much more nuanced. Some authors have
noted that service disengagement is a product of the complex interactions of a patient‟s
attitudes towards his or her illness, clinicians, and treatment (73).
The Service Engagement Scale is a metric developed for objectively and thoroughly
measuring engagement with services at community mental health centers. The scale
measures engagement as a function of several metrics, including the ease with which
patients can attend appointments, the perceived role of a patient in his or her care, a
patient‟s perceived need or desire to seek help, and a patient‟s willingness to follow
clinical advice and take medication. Evaluation of the scale has demonstrated that it is a
highly reliable and valid measure of service engagement among patients with
schizophrenia seeking treatment at a community mental health center (73).
It is imperative that future studies examining disengagement begin adopting more
consistent, reliable, and thorough measures of engagement and disengagement, allowing
for more meaningful meta-analyses and data interpretation. In addition, adopting a more
quantitative, nuanced measure of engagement may allow for more sensitive and specific
stratification of patients according to engagement levels, improving the allocation of
resources and outreach measures to those patients who will benefit most (73), or even
boosting statistical power of future disengagement studies employing relatively small
sample sizes. The current study was limited by not employing such a measure of
disengagement, and while we used a working definition that we believed would
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maximize our ability to identify patients who are truly disengaged from care, it‟s possible
that the use of SES would have provided a superior measure. Additionally, our definition
of disengagement allowed for a potential third group of patients: those who disengage
from care but eventually return. It may be worthwhile in future studies with larger
populations to either exclude these patients, or analyze them as a behaviorally distinct
third group to uncover predictive variables with greater power.
Finally, because we were primarily interested in the earlier, more critical periods for
establishing clinical contact, we limited follow-up to one year. While likelihood of
disengagement decreases as length of consistent clinical contact increases (24), we may
have uncovered higher rates of disengagement had we examined service use over a
longer period.
Conclusions
Specialized early intervention in psychosis is a growing trend in psychiatry, driven by the
potential for superior clinical outcomes and more efficient allocation of economic
resources. Much of the data on the benefit of early intervention is drawn from patient
populations in Australia, Europe, and Canada. Even with a lack of statistical power, it
appears that the factors that correlate with service disengagement in these countries may
be similarly predictive in the United States. Specifically, patients with lower baseline
GAF, longer DUP, forensic history, and less family contact may be more likely to
discontinue treatment for psychotic illness in the first year of initial outpatient treatment.
Early intervention clinics hoping to improve rates of service use do so via assertive
treatment methods, including frequent contact with case workers, letter and telephone
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reminders of appointments, and vocational assistance. By identifying factors at baseline
that associate with service disengagement, early intervention clinics will be able to
channel limited resources to those patients who are at higher risk of discontinuing care.
Future studies should seek to analyze the predictive power of these and other factors with
larger patient samples in the United States. More research should also assess which
interventions improve service use among at-risk patients, allowing for even more
efficient allocation of limited resources in these specialized clinics. Finally, future studies
should compare the clinical and functional outcomes of patients who disengage from care
those versus who do not. Although it is reasonable to suggest that a lack of regular
contact with healthcare providers may lead to worse outcomes in patients with psychosis,
additional data on the outcomes associated with disengagement is warranted, particularly
in the unique healthcare infrastructure of the United States. Such associations would be
beneficial in assessing the benefit of early intervention and other strategies to improve
clinical engagement.
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